Received May 18, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 4 | 2A3HY | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | 2A3HY | — |
Series repeated; Series repeated; This non-serious case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 66-year-old male patient who received Herpes zoster (Shingrix) (batch number NT357, expiry date 12-MAY-2028) and (batch number 2A3HY, expiry date 26-APR-2027) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) (batch number 2A3HY, expiry date 26-APR-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose of vaccine in 2019) and Shingrix (received 2nd dose of vaccine in 2019). On 07-MAY-2026, the patient received the 4th dose of Shingrix. On 05-FEB-2026, the patient received the 3rd dose of Shingrix. On 05-FEB-2026, an unknown time after receiving Shingrix and Shingrix, the patient experienced extra dose administered (Verbatim: Series repeated). On 07-MAY-2026, the patient experienced extra dose administered (Verbatim: Series repeated). The outcome of the extra dose administered and extra dose administered were not applicable. Additional Information: GSK Receipt Date: 08-MAY-2026 and 11-MAY-2026 The caller reported a duplicate vaccine series; the patient had received the series in 2019 and then received a complete series again.